August 10, 2021

Results from 16 Significant Vascular Interventional Clinical Trials to Be Presented for the First Time at VIVA21

SAN JOSE, CA, 8/10/21 -- Leading physicians and researchers will present results from 16 clinical trials focused on vascular interventional technology and treatment solutions on Tuesday, October 5, and Wednesday, October 6, at the 19th annual VIVA conference at Wynn Las Vegas. VIVA (Vascular InterVentional Advances) is an annual vascular education symposium that brings together a global, multispecialty faculty to present a variety of talks and live case presentations from clinical centers around the world. Attendees include an audience of interventional cardiologists, interventional radiologists, vascular surgeons, and endovascular medicine specialists.

Media outlets are invited to attend the presentations in person. The presentations will also be available to all VIVA attendees and invited press through the Virtual VIVA app. Any members of the press planning to attend or press who would like access the sessions virtually should contact To view the detailed schedule and register to attend, visit

Clinical trial results to be released (in order of presentation):

Tuesday, October 5

5-Year Outcomes from the IN.PACT Global Study Prespecified Cohorts: Chronic Total Occlusions, Long Lesions, and In-Stent Restenosis
Gunnar Tepe, MD

2-Year Results of the RANGER II SFA Randomized Trial: RANGER Drug-Coated Balloon vs Uncoated Balloons Overall and for Women, Patients with Occlusions, or Moderate/Severe Calcification
Ravish Sachar, MD

Racial Differences in Presentation and Outcomes After Peripheral Vascular Interventions: Insights from the NCDR-PVI Registry
Howard Julien, MD

Real-World Evaluation of Disparities in Critical Limb Ischemia Management Associated with Major Limb Amputation
Eric Secemsky, MD, MSc

KNOCOUT PE: Retrospective and Prospective International EKoSoNic® Registry of the Treatment and Clinical Outcomes of Patients with Pulmonary Embolism
Keith Sterling, MD

A Prospective Multicenter Trial of Pharmacomechanical Catheter-Directed Thrombolysis with the BASHIR™ Endovascular Catheter for Intermediate Risk Acute Pulmonary Embolism – Interim Analysis of The RESCUE Study
Akhilesh Sista, MD

5-Year VenaSeal Outcomes for Symptomatic Saphenous Incompetence: Is This the Clear Choice?
Morwan Bahi, MBChB

VIVO Clinical Study of the Zilver® Vena Venous Stent in the Treatment of Symptomatic Iliofemoral Venous Outflow Obstruction: 3-Year Outcomes
Paul Gagne, MD

Wednesday, October 6

IN.PACT AV Access Study 24-month Outcomes by Lesion Characteristics
Robert Lookstein, MD, MHCDL

The EMINENT Study: Primary Results of the Randomized Trial of Eluvia DES vs Bare Metal Stents
Yann Gouëffic, MD, PhD

Utility of Sirolimus Drug-Eluting Balloons in the Treatment of Complex Below-the-Knee Atherosclerotic Disease in Patients with Chronic Limb-Threatening Ischemia–18-Month Results from the PRESTIGE Study
Tjun Tang, MD

Intravascular Lithotripsy for Peripheral Artery Calcification: Interim Analysis of 752 Patients from the Disrupt PAD III Observational Study
Ehrin Armstrong, MD

2-Year PROMISE I Results with the LimFlow Deep Vein Arterialization System
Daniel Clair, MD

MIMICS-3D: Claudicants and CLI Patients Treated with BioMimics 3D Have Similar Patency at 2 Years
Michael Lichtenberg, MD

INSIGHT: Evaluation of the Pantheris OCT-Imaging Atherectomy System in Treatment of In-Stent Restenosis (ISR) Occlusions in Lower Extremity Arteries
Jon George, MD

Amplifi Treatment Prior to AVF Creation
Surendra Shenoy, MD, PhD

About VIVA Physicians

VIVA Physicians, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, strives to be the premier educator in the field. Our team of specialists in vascular medicine, interventional cardiology, interventional radiology, and vascular surgery is driven by the passion to advance the field and improve patient outcomes. Educational events presented by VIVA Physicians have a distinct spirit of collegiality attained by synergizing collective talents to promote awareness and innovative therapeutic options for vascular disease worldwide. To learn more about VIVA Physicians, visit